Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Peer Review reports

Original Submission
29 Mar 2016	Submitted	Original manuscript
28 Oct 2016	Author responded	Author comments - Bernies van der Hiel
Resubmission - Version 2
28 Oct 2016	Submitted	Manuscript version 2
1 Jun 2017	Reviewed	Reviewer Report - Hussein A Tawbi
3 Jul 2017	Reviewed	Reviewer Report - Robert R. McWilliams
14 Jul 2017	Author responded	Author comments - Bernies van der Hiel
Resubmission - Version 3
14 Jul 2017	Submitted	Manuscript version 3
4 Aug 2017	Reviewed	Reviewer Report - Robert R. McWilliams
25 Aug 2017	Author responded	Author comments - Bernies van der Hiel
Resubmission - Version 4
25 Aug 2017	Submitted	Manuscript version 4
Publishing
28 Aug 2017	Editorially accepted
15 Sep 2017	Article published	10.1186/s12885-017-3626-5

Back to article page